Hiroaki Iwata

Hiroaki Iwata

Auto-generated profile, based on publicly available information

Hiroaki Iwata

Department of Biological Regulation, Faculty of Medicine, Tottori University, 86 Nishi-cho, Yonago 683-8503, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2021 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
BMBiao Ma
Biao Ma
KTKei Terayama
Kei Terayama
SMShigeyuki Matsumoto
Shigeyuki Matsumoto
YIYuta Isaka
Yuta Isaka
YSYoko Sasakura
Yoko Sasakura
YOYasushi Okuno
Yasushi Okuno

22 August 2022 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
HIHiroaki Iwata
Hiroaki Iwata
TMTatsuru Matsuo
Tatsuru Matsuo
HMHideaki Mamada
Hideaki Mamada
TMTakahisa Motomura
Takahisa Motomura
MMMayumi Matsushita
Mayumi Matsushita
KHKoichi Handa
Koichi Handa
Pharmacokinetic research plays an important role in the development of new drugs. Accurate predictions of human pharmacokinetic parameters are essential for the success of clinical trials. Clearance (CL) and volume of distribution (Vd) are important factors for evaluating pharmacokinetic properties, and many previous studies have attempted to use computational methods to extrapolate these values from nonclinical laboratory animal models to human subjects. However, it is difficult to obtain sufficient, comprehensive experimental data from these animal models, and many studies are missing critical values. This means that studies using nonclinical data as explanatory variables can only apply a small number of compounds to their model training. In this study, we perform missing-value imputation and feature selection on nonclinical data to increase the number of training compounds and nonclinical datasets available for these kinds of studies. We could obtain novel models for total body clearance (CLtot) and steady-state Vd (Vdss) (CLtot: geometric mean fold error [GMFE], 1.92; percentage within 2-fold error, 66.5%; Vdss: GMFE, 1.64; percentage within 2-fold error, 71.1%). These accuracies were comparable to the conventional animal scale-up models. Then, this method differs from animal scale-up methods because it does not require animal experiments, which continue to become more strictly regulated as time passes.

1 April 2021 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
HIHiroaki Iwata
Hiroaki Iwata
TMTatsuru Matsuo
Tatsuru Matsuo
HMHideaki Mamada
Hideaki Mamada
TMTakahisa Motomura
Takahisa Motomura
MMMayumi Matsushita
Mayumi Matsushita
KHKoichi Handa
Koichi Handa
Research into pharmacokinetics plays an important role in the development process of new drugs. Accurately predicting human pharmacokinetic parameters from preclinical data can increase the success rate of clinical trials. Since clearance (CL) which indicates the capacity of the entire body to process a drug is one of the most important parameters, many methods have been developed. However, there are still rooms to be improved for practical use in drug discovery research; "improving CL prediction accuracy" and "understanding the chemical structure of compounds in terms of pharmacokinetics". To improve those, this research proposes a multimodal learning method based on deep learning that takes not only the chemical structure of a drug but also rat CL as inputs. Good results were obtained compared with the conventional animal scale-up method; the geometric mean fold error was 2.68 and the proportion of compounds with prediction errors of 2-fold or less was 48.5%. Furthermore, it was found to be possible to infer the partial structure useful for CL prediction by a structure contributing factor inference method. The validity of these results of structural interpretation of metabolic stability was confirmed by chemists.

22 November 2023 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
HIHiroaki Iwata
Hiroaki Iwata
TNTaichi Nakai
Taichi Nakai
TKTakuto Koyama
Takuto Koyama
SMShigeyuki Matsumoto
Shigeyuki Matsumoto
RKRyosuke Kojima
Ryosuke Kojima
YOYasushi Okuno
Yasushi Okuno
Molecular generation is crucial for advancing drug discovery, materials science, and chemical exploration. It expedites the search for new drug candidates, facilitates tailored material creation, and enhances our understanding of molecular diversity. By employing artificial intelligence techniques such as molecular generative models based on molecular graphs, researchers have tackled the challenge of identifying efficient molecules with desired properties. Here, we propose a new molecular generative model combining a graph-based deep neural network and a reinforcement learning technique. We evaluated the validity, novelty, and optimized physicochemical properties of the generated molecules. Importantly, the model explored uncharted regions of chemical space, allowing for the efficient discovery and design of new molecules. This innovative approach has considerable potential to revolutionize drug discovery, materials science, and chemical research for accelerating scientific innovation. By leveraging advanced techniques and exploring previously unexplored chemical spaces, this study offers promising prospects for the efficient discovery and design of new molecules in the field of drug development.

19 May 2025 in Current Research in Food Science
Verified
Journal Article
Open access
HIHiroaki Iwata
Hiroaki Iwata
Understanding the molecular mechanisms governing sweetness and bitterness is essential for identifying desirable taste characteristics in natural and synthetic compounds. In this study, we developed graph neural network (GNN)-based artificial intelligence (AI) models to predict bitterness and sweetness based on chemical structure. GNNs utilize deep learning to capture relationships among molecular components within a graph, extracting latent molecular vectors. Unlike conventional methods relying on predefined molecular descriptors, GNNs learn directly from molecular structures, reducing feature selection biases. By enhancing the interpretability of AI-driven predictions, GNNs improve understanding of decision-making. To construct GNN-based predictive models, we compiled datasets of compounds classified as either bitter or sweet. Our models achieved prediction accuracies comparable to or exceeding those of traditional machine learning and deep learning models that rely on molecular descriptors. To enhance model interpretability, we employed the Integrated Gradients method to visualize the molecular features influencing bitterness or sweetness predictions. These visualizations were further validated through molecular docking simulations of ligands on taste receptors, using the AlphaFold Protein Structure Database. Bitterness was evaluated using TAS2R16 and sweetness with TAS1R2. The chemical visualization results were then compared with conformational data, demonstrating strong alignment with previous experimental and computational analyses. These findings validate our AI model's accuracy and visualization outcomes, highlighting the potential of GNN-based models in taste prediction. This approach offers a novel framework for understanding the molecular mechanisms underlying taste perception. Further investigations are warranted to explore these mechanisms in greater depth and extend this methodology to predict additional taste modalities.

9 May 2025 in Molecular Pharmaceutics
Verified
Journal Article
Open access
HIHiroaki Iwata
Hiroaki Iwata
MKMichiharu Kageyama
Michiharu Kageyama
KHKoichi Handa
Koichi Handa
Recent research has increasingly focused on using machine learning for covariate selection in population pharmacokinetics (PPK) analysis. However, few studies have explored the prediction of plasma concentration profiles of drugs using nonlinear mixed-effect models combined with machine learning. This gap includes limited validation of prediction accuracy and applicability to diverse patient populations and dosing conditions. This study addresses these gaps by using remifentanil as a model drug and applying machine learning models to predict plasma concentration profiles based on virtual and real-world data. We created various training data sets for the virtual data by clustering based on the size and diversity of the test data set. Our results demonstrated high prediction accuracy for virtual and real-world data sets using Random Forest models. These results suggest that machine learning models are effective for large-scale data sets and real-world data with variable dosing times and amounts per patient. Considering the efficiency of machine learning, it offers a fit-for-purpose approach alongside traditional PPK methods, potentially enhancing future pharmacokinetic and pharmacodynamic studies.